OSI DPP-IV Inhibitor Is A “Sensible Approach” To Diabetes Dosing, Firm Says
The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said
You may also be interested in...
Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011